Correlation between peripheral inflammatory cytokines IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease
-
摘要:
目的 对帕金森病患者与健康对照者进行外周血IL-10、IL-32水平测定以及认知功能及非运动症状的评估，分析IL-10、IL-32水平与帕金森病认知功能障碍及非运动症状之间的相关性。 方法 选取2022年1月—2023年10月于蚌埠医科大学第一附属医院就诊的帕金森病患者60例作为PD组，健康体检者60例作为对照组。采用ELISA法检测2组受试者血清IL-10、IL-32浓度水平；使用简易智力状态检查表和运动症状评价量表评估2组研究对象的认知功能及非运动症状；使用秩相关法分析外周血炎性因子IL-10、IL-32与帕金森病认知功能障碍及非运动症状的相关性。 结果 PD组患者外周血中IL-10水平[136.60(117.05, 169.70)pg/mL]高于对照组[110.90(92.15, 129.50)pg/mL，P＜0.01]，PD组IL-32水平[32.35(28.83, 37.68)pg/mL]高于对照组[21.80(20.60, 23.35)pg/mL，P＜0.01]；PD患者外周血IL-10水平与MMSE[(20.68±6.33)分]评分及NMSS[(103.17±11.25)分]评分均呈正相关(P＜0.01)，PD患者外周血IL-32水平与MMSE评分及NMSS评分均呈正相关(P＜0.01)。 结论 PD患者外周血中炎性因子IL-10、IL-32水平较健康对照者高，并且与帕金森病认知功能障碍及非运动症状有密切的相关性。 Abstract:Objective To analyze the correlation between the levels of IL-10 and IL-32 and the cognitive dysfunction and non-motor symptoms of Parkinson' s disease (PD), we measured levels of IL-10 and IL-32 in the peripheral blood of Parkinson' s disease patients and healthy controls and evaluated their cognitive function and non-motor symptoms. Methods Sixty patients with Parkinson' s disease in the First Affiliated Hospital of Bengbu Medical University from January 2022 to October 2023 were selected as the observation group, and 60 healthy subjects were selected as the control group. Serum concentrations of IL-10 and IL-32 in the two groups were detected by ELISA. The cognitive function and non-motor symptoms of the two groups were evaluated using the simple mental state checklist and the motor symptom assessment scale. The correlation between peripheral inflammatory factors IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease was analyzed by hierarchical correlation method. Results The level of IL-10 in the peripheral blood of PD group was [136.60 (117.05, 169.70) pg/mL], which was higher than that of the control group [110.90 (92.15, 129.50) pg/mL, P < 0.01]. The level of IL-32 in the PD group was [32.35 (28.83, 37.68) pg/mL], which was higher than that in the control group [21.80 (20.60, 23.35) pg/mL, P < 0.01]. The level of IL-10 in the peripheral blood of PD patients was positively correlated with MMSE score (20.68±6.33) and NMSS score (103.17±11.25, P < 0.01). The level of IL-32 in the peripheral blood in PD patients was also positively correlated with MMSE score and NMSS score (P < 0.01). Conclusion The levels of inflammatory factors IL-10 and IL-32 in the peripheral blood of PD patients were higher than those of healthy controls, and were closely correlated with cognitive dysfunction and non-motor symptoms of PD. -
Key words:
- Parkinson' s disease /
- IL-10 /
- IL-32 /
- Cognitive dysfunction /
- Non-motor symptoms
-
表 1 PD组和对照组性别、年龄及文化程度比较
Table 1. Comparison of gender, age, and education level between PD group and control group
组别 例数 性别(男/女，例) 年龄(x±s，岁) 文化程度(小学及以下/初中/高中/本科，例) PD组 60 29/31 69.90±6.21 27/16/11/6 对照组 60 28/32 68.40±6.28 22/21/9/8 统计量 0.033a 1.315b 0.476c P值 0.855 0.191 0.490 注：a为χ2值，b为t值，c为Z值。 
下载: 导出CSV
表 2 PD组与对照组外周血中IL-10和IL-32水平比较[M(P25, P75)，pg/mL]
Table 2. Comparison of IL-10 and IL-32 levels in peripheral blood of PD group and control group [M(P25, P75), pg/mL]
组别 例数 IL-10 IL-32 PD组 60 136.60(117.05, 169.70) 32.35(28.83, 37.68) 对照组 60 110.90(92.15, 129.50) 21.80(20.60, 23.35) Z值 -4.850 -9.404 P值 ＜0.001 ＜0.001
下载: 导出CSV
表 3 PD组与对照组MMSE评分比较[例(%)]
Table 3. Comparison of MMSE scores between PD group and control group [cases (%)]
组别 例数 MMSE评分
重度: ≤9分MMSE评分
中度: 10~20分MMSE评分
轻度: 21~26分MMSE评分
正常: ≥27分PD组 60 8(13.33) 15(25.00) 28(46.66) 9(15.00) 对照组 60 0 2(3.33) 11(18.33) 47(78.33) Z值 49.716 P值 ＜0.001
下载: 导出CSV
-
[1] ZHENG Z, ZHANG S, ZHANG H, et al. Mechanisms of autoimmune cell in DA neuron apoptosis of Parkinson' s disease: recent advancement[J]. Oxid Med Cell Longev, 2022, 2022: 7965433. DOI: 10.1155/2022/7965433. [2] SEVERIANO E SOUSA C, ALARCÀO J, PAVÀO MARTINS I, et al. Frequency of dementia in Parkinson' s disease: a systematic review and meta-analysis[J]. J Neurol Sci, 2022, 432: 120077. DOI: 10.1016/j.jns.2021.120077. [3] GOLDMAN J G, SIEG E. Cognitive impairment and dementia in Parkinson disease[J]. Clin Geriatr Med, 2020, 36(2): 365-377. doi: 10.1016/j.cger.2020.01.001 [4] KOULI A, CAMACHO M, ALLINSON K, et al. Neuroinflammation and protein pathology in Parkinson' s disease dementia[J]. Acta Neuropathol Commun, 2020, 8(1): 211. doi: 10.1186/s40478-020-01083-5 [5] JURCAU A, ANDRONIE-CIOARA F L, NISTOR-CSEPPENTO D C, et al. The involvement of neuroinflammation in the onset and progression of Parkinson' s disease[J]. Int J Mol Sci, 2023, 24(19): 14582. DOI: 10.3390/ijms241914582. [6] WILLIAMS G P, SCHONHOFF A M, JURKUVENAITE A, et al. Targeting of the class Ⅱ transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson' s disease[J]. J Neuroinflammation, 2018, 15(1): 244. doi: 10.1186/s12974-018-1286-2 [7] WANG J, LAI S, ZHOU T, et al. Progranulin from different gliocytes in the nucleus accumbens exerts distinct roles in FTD and neuroinflammation-induced depression-like behaviors[J]. J Neuroinflammation, 2022, 19(1): 318. doi: 10.1186/s12974-022-02684-8 [8] DE ALBUQUERQUE R, KOMSI E, STARSKAIA I, et al. The role of interleukin-32 in autoimmunity[J]. Scand J Immunol, 2021, 93(2): e13012. DOI: 10.1111/sji.13012. [9] 刘军. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002LIU J. Diagnostic criteria for Parkinson' s disease in China (2016 edition)[J]. Chinese Journal of Neurology, 2016, 49(4): 268-271. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002 [10] LIU X, LE W. Profiling non-motor symptoms in monogenic Parkinson' s disease[J]. Front Aging Neurosci, 2020, 12: 591183. DOI: 10.3389/fnagi.2020.591183. [11] MADABUSHI J S, GUPTA M, PEARCE B, et al. Parkinson' s disease: diagnostic challenges amidst transdiagnostic and overlapping mental health symptoms[J]. Cureus, 2023, 15(3): e36661. DOI: 10.7759/cureus.36661. [12] 王伟, 曹庆华, 孙光玲, 等. 脑白质病变与帕金森病患者运动症状及非运动症状的相关性分析[J]. 中华全科医学, 2022, 20(2): 237-239. doi: 10.16766/j.cnki.issn.1674-4152.002321WANG W, CAO Q H, SUN G L, et al. Correlation analysis of white matter lesions and motor symptoms and non-motor symptoms in Parkinson' s patients[J]. Chinese Journal of General Practice, 2022, 20(2): 237-239. doi: 10.16766/j.cnki.issn.1674-4152.002321 [13] CHEN X, HU Y, CAO Z, et al. Cerebrospinal fluid inflam-matory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. Front Immunol (2018)9: 2122. DOI: 10.3389/fimmu.2018.02122. [14] LIU H J, LI X Y, CHEN H, et al. Identification of susceptibility loci for cognitive impairment in a cohort of Han Chinese patients with Parkinson' s disease[J]. Neurosci Lett, 2020, 730: 135034. DOI: 10.1016/j.neulet.2020.135034. [15] SHU L, LIANG D, PAN H, et al. Gastrointestinal dysfunctions are associated with IL-10 variants in Parkinson' s disease[J]. Parkinsons Dis, 2018, 2018: 5908359. DOI: 10.1155/2018/5908359. [16] WANG B, CHEN T, WANG J, et al. Methamphetamine modulates the production of interleukin-6 and tumor necrosis factor-alpha via the cAMP/PKA/CREB signaling pathway in lipopolysaccharide-activated microglia[J]. Int Immunopharmacol, 2018, 56: 168-178. doi: 10.1016/j.intimp.2018.01.024 [17] WANG M, PAN W, XU Y, et al. Microglia-mediated neuroinflammation: a potential target for the treatment of cardiovascular diseases[J]. J Inflamm Res, 2022, 15: 3083-3094. doi: 10.2147/JIR.S350109 [18] ZHU H, HU S, LI Y, et al. Interleukins and ischemic stroke[J]. Front Immunol, 2022, 13: 828447. DOI: 10.3389/fimmu.2022.828447. [19] GAUTAM A, PANDIT B. IL32: The multifaceted and unconventional cytokine[J]. Hum Immunol, 2021, 82(9): 659-667. doi: 10.1016/j.humimm.2021.05.002 [20] JSRIVASTAVA S, RASOOL M. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis[J]. Life Sci, 2022, 298: 120516. DOI: 10.1016/j.lfs.2022.120516. [21] DE ALBUQUERQUE R, KOMSI E, STARSKAIA I, et al. The role of Interleukin-32 in autoimmunity[J]. Scand J Immunol, 2021, 93(2): e13012. DOI: 10.1111/sji.13012. [22] KWON O C, PARK M C, KIM Y G. Interleukin-32 as a biomarker in rheumatic diseases: a narrative review[J]. Front Immunol, 2023, 14: 1140373. DOI: 10.3389/fimmu.2023.1140373. [23] TIAN Z J, SHEN Y, LI X R, et al. Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers[J]. J Infect Public Health, 2019, 12(1): 7-12. doi: 10.1016/j.jiph.2018.06.006 [24] DU J, SHAO M M, YI F S, et al. Interleukin 32 as a potential marker for diagnosis of tuberculous pleural effusion[J]. Microbiol Spectr, 2022, 10(4): e0255321. DOI: 10.1128/spectrum.0255321. [25] ADAWY A, LI L, HIRAO H, et al. Potential involvement of IL-32 in cell-to-cell communication between macrophages and hepatoblastoma[J]. Pediatr Surg Int, 2023, 39(1): 275. doi: 10.1007/s00383-023-05557-0 [26] LIU C, XU X, HUANG C, et al. Inhibition of IL-32 expression ameliorates cerebral ischemia-reperfusion injury via the NOD/MAPK/NF-κB signaling pathway[J]. J Mol Neurosci, 2020, 70(11): 1713-1727. doi: 10.1007/s12031-020-01557-0 -
点击查看大图
表(3)
计量
- 文章访问数: 2
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0
